$AGMB

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

Agomab Therapeutics said it has aligned with the FDA on the design of its NOV-ERA Phase 2b trial of ontunisertib for fibrostenosing Crohn’s disease, including a primary endpoint of endoscopic passability at Week 24. The randomized, double-blind study plans up to 320 adults and dosing begins in the second half of 2026.

AgomAb Therapeutics NV (NASDAQ:AGMB) secured a U.S. patent for its investigational drug AGMB-447, an ALK5 inhibitor for idiopathic pulmonary fibrosis, providing protection through at least 2041. This news follows optimistic analyst coverage from Leerink and JPMorgan, who issued Outperform and Overweight ratings, respectively, citing upcoming data readouts and promising pipeline developments. The company is poised for a significant year in 2026 with potential upsides in its treatments for fibrotic and inflammatory bowel diseases.

Leerink has initiated coverage on AgomAb Therapeutics (NASDAQ: AGMB) with an "Outperform" rating and a price target of $36. This announcement comes alongside similar "Overweight" initiations from JPMorgan and Morgan Stanley on the same day, indicating positive analyst sentiment for the biotechnology company. AgomAb had recently completed a $200 million IPO in early February.

Stifel analyst James Condulis initiated coverage on Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) with a Buy rating and a $21 price target. This article also highlights three other significant analyst initiations for Tuesday, including Goldman Sachs on Once Upon A Farm PBC (NYSE: OFRM), Morgan Stanley on Agomab Therapeutics NV (NASDAQ: AGMB), and Stifel on SpyGlass Pharma, Inc. (NASDAQ: SGP), all with bullish ratings and specific price targets.